Beta Bionics Q3 Sales Up 30% to $35.5M; Loss Widens to $24.4M, Cash at $373.6M
BBNX has more than doubled off its 52-week low of $8.8.
Summary
Beta Bionics grew Q3 sales 30% to $35.5M but the operating loss widened to $26.6M, and the 10-Q formally discloses a securities class action plus new executive 10b5-1 selling plans. Cash and investments of $373.6M fund the Mint launch into 2027.
Key Events · Earnings and Guidance · BBNX
-
Q3 Sales Up 30% to $35.5M
Net sales rose to $35.5 million from $27.3 million a year ago; nine-month sales reached $95.1 million, up 40% from $68.1 million.
-
Operating Loss Widens to $26.6M
Loss from operations was $26.6 million, or negative 75% of sales, versus $17.0 million (negative 63%) a year ago; net loss was $24.4 million, or $0.52 per share.
-
Cash and Investments of $373.6M
September's follow-on added roughly $161.3 million net, bringing cash, cash equivalents and short-term and long-term investments to $373.6 million as of September 30, 2026.
-
Securities Class Action Disclosed
The Holtzman v. Beta Bionics suit, filed September 2026, alleges 10(b)/20(a) and Rule 10b-5 violations over iLet safety, efficacy and commercial success statements; loss is not currently probable or estimable.
Analysis · BBNX · Industrial Applications And Services
Revenue growth is real — Q3 net sales of $35.5M rose 30% and the pharmacy channel now carries 38% of nine-month sales versus 21% a year ago — but the cost of that growth is visible: the operating loss widened to $26.6M, or negative 75% of sales, from $17.0M a year ago, and sales and marketing alone ran $25.1M. The September follow-on raised roughly $161.3M net, lifting cash and investments to $373.6M, which funds the Mint patch-pump launch planned for Q1 2027 and the withdrawn-then-resubmitted 3D Intelligence 510(k) without near-term financing pressure. Against that, the 10-Q formally books the September securities class action over iLet safety and efficacy claims, and three executives adopted 10b5-1 selling plans in the quarter — a stock that already fell sharply on the safety disclosure now carries litigation and insider-selling overhangs.
How filings like this one have moved
In the 30 days to Oct 28, 2026, 36.5% of the 953 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.66%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BBNX was trading at $18.92 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $8.80 to $32.71. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.